Innovative ‘breakthrough’ cell therapy for difficult-to-treat cancers rejected for NHS use
A “new generation” cancer therapy has been rejected for widespread NHS use by health officials. The National Institute for Health and Care Excellence (Nice) published draft guidance stating that axicabtagene
Read More